Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function

Trial Profile

Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Chronic heart failure; Renal impairment
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2016 Planned End Date changed from 1 Apr 2017 to 1 Mar 2017.
    • 08 Aug 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Mar 2017.
    • 18 Dec 2015 Planned End Date changed from 1 Apr 2014 to 1 Apr 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top